Summary
Airborne viruses causing respiratory diseases represent a mayor global health threat, being viruses with RNA-genomes from animal reservoirs highly likely to cause further public health emergencies in the future. VIR-Quantify aims to provide proof of concept for a technology capable of highly sensitive, fast and untargeted airborne virus detection with infectivity assessment, providing a comparative advantage in the competitive landscape. VIR-Quantify builds upon an unprecedented application of NMS sensors to the field of airborne viral particles detection (methodology developed and patented by the PI in the framework of a previous ERC CoG).
VIR-Quantify proposes the use of ionic liquids to preserve the virus structure, together nanowire sensors that allow mass and stiffness measurements for identification and infectivity studies of the pathogens. The innovative solution lies in two fronts: 1) an unprecedented capability to measure with high throughput (30 particles/minute) the stiffness of intact viruses to infer their infectivity potential, not at reach to other techniques, 2) the capability to count and characterize all the viral particles present in the liquid sample without loss of bioanalytes during the measurements.
VIR-Quantify aims to exploit the novel technology for on-site identification and quantification of airbone viral particles and validate the innovation potential of such technological tool for commercialization by developing a market entry strategy built upon IPR consolidation and spin-off set-up. This will lead to high-gain, disruptive outcomes in the form of unprecedented mechanistic understanding for detecting the quick spread of airbone viral particles with great socioeconomic benefits visible at three levels: (1) fuelling industrial innovation and economic growth in a game-changing sector (preventive medicine); (2) reducing healthcare costs worldwide, thus enabling more resilient and efficient health systems; (3) improving human welfare.
VIR-Quantify proposes the use of ionic liquids to preserve the virus structure, together nanowire sensors that allow mass and stiffness measurements for identification and infectivity studies of the pathogens. The innovative solution lies in two fronts: 1) an unprecedented capability to measure with high throughput (30 particles/minute) the stiffness of intact viruses to infer their infectivity potential, not at reach to other techniques, 2) the capability to count and characterize all the viral particles present in the liquid sample without loss of bioanalytes during the measurements.
VIR-Quantify aims to exploit the novel technology for on-site identification and quantification of airbone viral particles and validate the innovation potential of such technological tool for commercialization by developing a market entry strategy built upon IPR consolidation and spin-off set-up. This will lead to high-gain, disruptive outcomes in the form of unprecedented mechanistic understanding for detecting the quick spread of airbone viral particles with great socioeconomic benefits visible at three levels: (1) fuelling industrial innovation and economic growth in a game-changing sector (preventive medicine); (2) reducing healthcare costs worldwide, thus enabling more resilient and efficient health systems; (3) improving human welfare.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101157423 |
| Start date: | 01-07-2024 |
| End date: | 31-12-2025 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
Airborne viruses causing respiratory diseases represent a mayor global health threat, being viruses with RNA-genomes from animal reservoirs highly likely to cause further public health emergencies in the future. VIR-Quantify aims to provide proof of concept for a technology capable of highly sensitive, fast and untargeted airborne virus detection with infectivity assessment, providing a comparative advantage in the competitive landscape. VIR-Quantify builds upon an unprecedented application of NMS sensors to the field of airborne viral particles detection (methodology developed and patented by the PI in the framework of a previous ERC CoG).VIR-Quantify proposes the use of ionic liquids to preserve the virus structure, together nanowire sensors that allow mass and stiffness measurements for identification and infectivity studies of the pathogens. The innovative solution lies in two fronts: 1) an unprecedented capability to measure with high throughput (30 particles/minute) the stiffness of intact viruses to infer their infectivity potential, not at reach to other techniques, 2) the capability to count and characterize all the viral particles present in the liquid sample without loss of bioanalytes during the measurements.
VIR-Quantify aims to exploit the novel technology for on-site identification and quantification of airbone viral particles and validate the innovation potential of such technological tool for commercialization by developing a market entry strategy built upon IPR consolidation and spin-off set-up. This will lead to high-gain, disruptive outcomes in the form of unprecedented mechanistic understanding for detecting the quick spread of airbone viral particles with great socioeconomic benefits visible at three levels: (1) fuelling industrial innovation and economic growth in a game-changing sector (preventive medicine); (2) reducing healthcare costs worldwide, thus enabling more resilient and efficient health systems; (3) improving human welfare.
Status
SIGNEDCall topic
ERC-2023-POCUpdate Date
12-03-2024
Images
No images available.
Geographical location(s)
